ImpeDx Diagnostics Announces Promotions, Swiger CEO, and Board Additions

January 2019

ImpeDx Diagnostics is pleased to announce the promotion of Dr. Roy Swiger to CEO of the Company.   Dr. Steve O’Connor will remain active with the company and is taking on the role of Executive Chairman.

“Roy has demonstrated operational and strategic excellence, both at his past positions and with ImpeDx.   The Board is very excited that he has accepted this new role”, stated Dr. O’Connor (Founder). 

Dr. O’Connor also announced the expansion of the ImpeDx Board of Directors, with the additions of Dr. Wayne Carter and Dr. Swiger.  “Wayne has excellent experience and will provide ImpeDx key strategic assistance as we continue to grow.”

To date, ImpeDx has raised ~$5.3M to develop our core platform.   This funding has come from a variety of sources including equity investment, non-dilutive government funding, and corporate partnerships.   


Overland Park, KS – ImpeDx Diagnostics (a privately held company) is developing a multiplexed phenotypic diagnostic system to perform extremely rapid Antibiotic Susceptibility Testing (AST) on a variety of different patient sample types (blood, urine, sputum, etc.) that will allow clinicians to provide targeted, effective antibiotics to patients in hours, rather than days or weeks as with currently available products.   Our system compliments existing rapid pathogen identification systems already on the market and provides the full answer clinicians require in order to implement appropriate patient care, improving patient outcomes while substantially reducing healthcare costs and the fostering of antibiotic resistance.  For more information, visit


ImpeDx Diagnostics

Dr. Roy Swiger, CEO

(321) 749-0523